Industry
Biotechnology
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
March 20, 2024 | 12:17 pm
Portfolio Pulse from Benzinga Newsdesk
March 18, 2024 | 8:01 pm
Portfolio Pulse from Benzinga Newsdesk
March 13, 2024 | 8:01 pm
Portfolio Pulse from Benzinga Newsdesk
March 08, 2024 | 5:48 pm
Portfolio Pulse from Benzinga Insights
February 19, 2024 | 5:30 pm
Portfolio Pulse from Benzinga Insights
February 19, 2024 | 1:05 pm
Portfolio Pulse from Avi Kapoor
February 16, 2024 | 6:04 pm
Portfolio Pulse from Benzinga Insights
February 16, 2024 | 5:31 pm
Portfolio Pulse from Vandana Singh
February 16, 2024 | 4:30 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.